Economic Impact of Early-in-Hospital Diagnosis and Initiation of Eculizumab in Atypical Haemolytic Uraemic Syndrome

BACKGROUND: Atypical haemolytic uraemic syndrome (aHUS) is a rare, potentially life-threatening condition caused by dysregulation of the complement pathway. Eculizumab is currently the only approved treatment for this disorder. OBJECTIVE: Our objective was to investigate the impact of early administ...

Descripción completa

Detalles Bibliográficos
Autores principales: Ryan, Michael, Donato, Bonnie M. K., Irish, William, Gasteyger, Christoph, L’Italien, Gilbert, Laurence, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045788/
https://www.ncbi.nlm.nih.gov/pubmed/31828738
http://dx.doi.org/10.1007/s40273-019-00862-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045788/
https://www.ncbi.nlm.nih.gov/pubmed/31828738
http://dx.doi.org/10.1007/s40273-019-00862-w

Ejemplares similares